Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03481803
Other study ID # MS1819/16/01
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date January 27, 2017
Est. completion date June 29, 2018

Study information

Verified date September 2018
Source AzurRx SAS
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase IIa study sponsored by AzurRx SAS and Syneos Health is a local representative sponsor and involves testing of a new medication for the compensation of exocrine pancreatic insufficiency (EPI) caused by chronic pacreatitis (CP) and/or distal pancreatectomy. The new medication is called MS1819 Spray Dried (MS1819-SD) which is a lipase produced by the LIP2 gene of Yarrowia lipolytica using recombinant DNA technology.

The primary purpose of this study is to investigate the safety of escalating doses of study drug MS1819-SD in people with chronic pancreatitis. This enzyme has demonstrated an appropriate profile to compensate the pancreatic lipase (enzyme) deficiency that is common with CP patients. The deficiency in this enzyme can be responsible of greasy diarrhea, fecal urge and weight loss.

The design of the study is open-label, meaning that all eligible participants will receive the study drug MS1819-SD. The MS1819-SD dose will increase throughout the study during dose escalation visits in each treatment period; study includes a total of four treatment periods.

The total duration of the MS1819-SD treatment phase is of 48-60 days, The total duration of patient participation in the study is of 74-93 days.

Approximately twelve patients will be enrolled in this study.


Recruitment information / eligibility

Status Completed
Enrollment 11
Est. completion date June 29, 2018
Est. primary completion date June 29, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Signed and dated informed consent form,

2. Age >18 years,

3. Male or female,

4. Body weight within the range [50-100 Kg] for males or [40-90 Kg] for females,

5. Distal pancreatectomy for any disorder (e.g. acute pancreatitis or its complications, CP or its complications, pancreatic endocrine or exocrine cancer, or others) and/or CP of any etiology (e.g. alcohol, genetics, hypercalcemia, or others) of grade 2 or higher (Cambridge classification),

6. Faecal pancreatic elastase-1 <100 µg/g of stools at screening or within one month of the screening visit,

7. CFA measurement = 75% at washout

8. Female patients must be post-menopausal (defined as at least 12 months post cessation of menses), surgically sterile or, if of childbearing potential, using a reliable method of contraception during the study.

9. Being considered as reliable and capable of adhering to the protocol, according to the judgment of the investigator.

Exclusion Criteria:

1. Cystic fibrosis,

2. Total or partial gastrectomy,

3. Cephalic or total duodenopancreatectomy,

4. Documented fibrosing colonopathy,

5. Any small bowel disease possibly responsible for malabsorption, including small intestinal bacterial overgrowth, celiac disease, small bowel resection =1 meter length, etc.,

6. Acute pancreatitis or exacerbation of CP =3 months,

7. Pancreatectomy for exocrine or endocrine cancer =1 year,

8. Metastatic or locally recurrent exocrine pancreatic cancer,

9. Known hypersensitivity or other severe reaction to any ingredient of the investigational medicinal product,

10. Bilirubin >3 times ULN (upper limit normal),

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
MS1819-SD
Patient will receive increasing doses from the lowest dose of MS1819-SD to a maximum dose of MS1819- SD. The total treatment phase will range from 48 days to 60 days.

Locations

Country Name City State
Australia CMAX Adelaide South Australia
Australia Mackay Institute of Research and Innovation Mackay Queensland
Australia Linear Research Perth Western Australia
France Ho^pital Timone Adulte (CIC-CPCET) Marseille
New Zealand Christchurch Clinical Studies Trust Christchurch
New Zealand P3 Research Wellington

Sponsors (1)

Lead Sponsor Collaborator
AzurRx SAS

Countries where clinical trial is conducted

Australia,  France,  New Zealand, 

Outcome

Type Measure Description Time frame Safety issue
Primary Investigate safety of escalating doses of MS1819-SD as measured by number of participants with adverse events including clinical or laboratory abnormalities Safety variables will be monitored by physical examination with particular attention paid to immunoallergic events and digestive symptomatology. In addition, laboratory tests will include haematology and biochemistry. 60 days
Secondary Investigate the efficacy of MS1819-SD in patients by the Coefficient of Fat Absorption change from baseline The primary efficacy endpoint is the Coefficient Fat Absorption (CFA) change from baseline.The secondary efficacy endpoints are the number of daily evacuations per day, the consistency of stools assessed by the Bristol scale (from Type 1 to Type 7) and the weight of stools during the stool collection period. 60 days
See also
  Status Clinical Trial Phase
Completed NCT03112759 - Assessing the Utility of Cognitive Behavioral Therapy for Pain Control in Patients With Chronic Pancreatitis N/A
Enrolling by invitation NCT05410795 - Establishment and Verification of Pancreatic Volume Formula Based on Imaging
Active, not recruiting NCT02965898 - The Effect of Vitamin D Substitution on the Development of Chronic Pancreatitis N/A
Completed NCT02868047 - Establishing Standards for Normal Pancreatic EUS N/A
Completed NCT01452217 - Non-invasive MRI to Quantify the Effect of Secretin on Pancreatic Blood Flow and Perfusion in Healthy Volunteers Phase 1
Completed NCT00685087 - A Prospective Study of Natural History of Pancreatitis N/A
Completed NCT04949828 - Effect of CREON on Exocrine Pancreatic Insufficiency (EPI) Symptoms
Recruiting NCT06068426 - Incorporating Endoscopic Ultrasound and Elastography Towards Improving Outcomes of Pediatric Pancreatitis Management N/A
Active, not recruiting NCT05764629 - An Observational Study on Post-chronic Pancreatitis Diabetes Mellitus
Active, not recruiting NCT05042284 - Effect of Non-enteric Coated Enzymes Substitution on Pain in Patients With Chronic Pancreatitis N/A
Completed NCT03850977 - Is There an Association Between Chronic Pancreatitis and Pulmonary Function
Recruiting NCT05692596 - The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
Recruiting NCT06015945 - Role of Home-based Transcutaneous Electrical Acustimulation for Treatment of Pain in Patients With Chronic Pancreatitis N/A
Completed NCT04619511 - Risk Factors for Post-ESWL and Post-ERCP Pancreatitis
Completed NCT03283566 - Hydroxychloroquine and Metabolic Outcomes in Patients Undergoing TPAIT Phase 2
Recruiting NCT03434392 - QST Study: Predicting Treatment Response in Chronic Pancreatitis Using Quantitative Sensory Testing N/A
Completed NCT01318369 - Efficacy Study of Δ9-THC to Treat Chronic Abdominal Pain Phase 2
Completed NCT01430234 - Enzyme Suppletion in Exocrine Pancreatic Dysfunction Phase 4
Terminated NCT01442454 - Endoscopic Ultrasound (EUS) Features of Chronic Pancreatitis N/A
Completed NCT00755573 - Pain and Chronic Pancreatitis - Clinical End Experimental Studies Phase 2/Phase 3